PTC’s Gene Expression Technology Wins Over Roche and Celgene
By Taskin Ahmed
Pharma Deals Review: Vol 2009 Issue 9 (Table of Contents)
Published: 17 Sep-2009
DOI: 10.3833/pdr.v2009.i9.1245 ISSN: 1756-7874
Section: Technology Access
Fulltext:
Abstract
PTC Therapeutics enters into two agreements with its Gene Expression Modulation by Small-molecules (GEMS™) technology: one with Roche to develop central nervous system products and another with Celgene for research into oncology targets...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS